Functional bowel disorders (FBD) resemble a group of diseases of the gastrointestinal (GI) tract that are without a clear pathogenesis; the best known is probably the “irritable bowel syndrome” (IBS). Only recently we have been able to explore the role of the gut microbiota in FBD due to progress in microbiological analytic techniques. There are different ways to explore the role of the gut microbiota and its dysbiosis in FBD. Comparison of the microbial composition in a group of patients with FBD, for example, with IBS to a group of healthy volunteers is one way. Studies have shown that the microbiota in FBD is different from that of healthy controls, but the recorded differences are not necessarily specific for FBD, they may also occur in other diseases. Another approach to explore the role of the gut microbiota in FBD is to challenge the existing “flora” with novel bacteria (probiotics) or with nutritional substrates that stimulate bacterial growth (prebiotics). More than 60 such trials including several thousand patients have been performed in IBS. These studies have produced mixed outcome: some probiotics appear to be better than others, and some appear to work only for a part of the IBS symptoms and not for all. An extreme form of this approach is the transfer of an entire microbiota from 1 healthy person to another, called fecal microbiota transplantation. This has rarely been tested in FBD but is not without risk in benign disorders.

Keywords:
Functional gastrointestinal diseases, Irritable bowel syndrome, Microbiota, Dysbiosis, Probiotics, Fecal microbiota transplantation
1.
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al: Irritable bowel syndrome. Nat Rev Dis Primers 2016; 2: 16014.
2.
Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G, et al: Functional dyspepsia. Nat Rev Dis Primers 2017; 3: 17081.
3.
Chey WD, Kurlander J, Eswaran S: Irritable bowel syndrome: a clinical review. JAMA 2015; 313: 949–958.
4.
Lovell RM, Ford AC: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–721.e4.
5.
Cryan JF, Dinan TG: Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701–712.
6.
Farmer AD, Randall HA, Aziz Q: It’s a gut feeling: how the gut microbiota affects the state of mind. J physiol 2014; 592(14):2981–2988.
7.
Corsetti M, Van Oudenhove L, Tack J: The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 2014; 26: 1669–1676.
8.
Rajilic-Stojanovic M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, et al: Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 2015; 110: 278–287.
9.
Thomas V, Clark J, Dore J: Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies. Future Microbiol 2015; 10: 1485–1504.
10.
Lee KJ, Tack J: Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 493–498.
11.
Casen C, Vebo HC, Sekelja M, Hegge FT, Karlsson MK, Ciemniejewska E, et al: Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther 2015; 42: 71–83.
12.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59–65.
13.
Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, et al: Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–1801.
14.
Jeffery IB, O’Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al: An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.
15.
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al: Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559–563.
16.
Power SE, O’Toole PW, Stanton C, Ross RP, Fitzgerald GF: Intestinal microbiota, diet and health. Br J Nutr 2014; 111: 387–402.
17.
Hayes P, Corish C, O’Mahony E, Quigley EM: A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet 2014; 27(suppl 2):36–47.
18.
Sood R, Gracie DJ, Law GR, Ford AC: Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015; 42: 491–503.
19.
Zimmer J, Lange B, Frick JS, Sauer H, Zimmermann K, Schwiertz A, et al: A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53–60.
20.
Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, et al: ­Randomised clinical trial: gut microbiome ­biomarkers are associated with clinical ­response to a low FODMAP diet in ­children with the irritable bowel syndrome. ­Aliment Pharmacol Ther 2015; 42: 418–427.
21.
Dey N, Wagner VE, Blanton LV, Cheng J, Fontana L, Haque R, et al: Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel. Cell 2015; 163: 95–107.
22.
Riddle MS, Connor BA: The Traveling Microbiome. Curr Infect Dis Rep 2016; 18: 29.
23.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027–1031.
24.
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI: Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11070–11075.
25.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022–1033.
26.
Sze MA, Schloss PD: Looking for a signal in the noise: revisiting obesity and the microbiome. MBio 2016; 7:pii:e01018–e01116.
27.
Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al: Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry 2016; 21: 786–796.
28.
Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al: Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015; 48: 186–194.
29.
Lloyd-Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, et al: Strains, functions and dynamics in the expanded human microbiome project. Nature 2017; 550: 61–66.
30.
Bennet SMP, Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, et al: Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut 2017, Epub ahead of print.
31.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al: Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506–514.
32.
Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al: Expert consensus document: The international ­scientific association for probiotics and ­prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017; 14: 491–502.
33.
Food and Agriculture Organisation WHO: Evaluation of Health and Nutritional Properties of Probiotics in Food, Including Powder Milk with Live Lactic Acid Bacteria. Geneva, WHO, 2001.
34.
Thompson WG: The road to rome. Gastroenterology 2006; 130: 1552–1556.
35.
Tack J, Fried M, Houghton LA, Spicak J, Fisher G: Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. Aliment Pharmacol Ther 2006; 24: 183–205.
36.
Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981–988.
37.
Oksanen PJ, Salminen S, Saxelin M, Hamalainen P, Ihantola-Vormisto A, Muurasniemi-Isoviita L, et al: Prevention of travellers’ diarrhoea by Lactobacillus GG. Ann Med 1990; 22: 53–56.
38.
Isolauri E, Kaila M, Mykkanen H, Ling WH, Salminen S: Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci 1994; 39: 2595–2600.
39.
McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–1918.
40.
Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T: A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90–97.
41.
Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, et al: Change of fecal flora and effectiveness of the short-term VSL#3 probiotic treatment in patients with functional constipation. J Neurogastroenterol Motil 2015; 21: 111–120.
42.
Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853–858.
43.
Mazurak N, Broelz E, Storr M, Enck P: Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about It? J Neurogastroenterol Motil 2015; 21: 471–485.
44.
Enck P, Zimmermann K, Menke G, Muller-Lissner S, Martens U, Klosterhalfen S: A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome – a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008; 20: 1103–1109.
45.
Tarrerias AL, Costil V, Vicari F, Letard JC, Adenis-Lamarre P, Aisene A, et al: The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome. Dig Dis 2011; 29: 588–591.
46.
Zoppi G, Cinquetti M, Benini A, Bonamini E, Minelli EB: Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. Curr Ther Res Clin E 2001; 62: 418–435.
47.
Weimer K, Enck P: Traditional and innovative experimental and clinical trial designs and their advantages and pitfalls. Handb Exp Pharmacol 2014; 225: 237–272.
48.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, et al: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581–1590.
49.
Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ: A randomized, double-blind, placebo-controlled multicenter trial of boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011; 45: 679–683.
50.
Ducrotte P, Sawant P, Jayanthi V: Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18: 4012–4018.
51.
Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG: A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 2010; 10: 16.
52.
Niedzielin K, Kordecki H, Birkenfeld B: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143–1147.
53.
Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231–1238.
54.
Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO: Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615–2620.
55.
Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S: Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition 2014; 30: 1151–1157.
56.
World Health Organisation (WHO): Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation – FAO Food and Nutrition Paper 85. Rome, WHO, 2006.
57.
Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T: The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med 2012; 6: 16.
58.
Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME: Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 1579–1585.
59.
Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al: Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714–2718.
60.
Niv E, Naftali T, Hallak R, Vaisman N: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925–931.
61.
O’Sullivan MA, O’Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 294–301.
62.
Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A: ­Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 2012; 18: 2067–2075.
63.
Guglielmetti S, Mora D, Gschwender M, Popp K: Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123–1132.
64.
Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, et al: Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29: 104–114.
65.
Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al: Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475–486.
66.
Charbonneau D, Gibb RD, Quigley EM: Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 2013; 4: 201–211.
67.
Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, et al: Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 2014; 26: 630–639.
68.
Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M: Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J 2011; 20: 397–401.
69.
Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, et al: A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015; 47: 119–124.
70.
Gade J, Thorn P: Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989; 7: 23–26.
71.
Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J: A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27: 467–474.
72.
Enck P, Zimmermann K, Menke G, Klosterhalfen S: Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009; 47: 209–214.
73.
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541–551.
74.
Wassenaar TM, Beimfohr C, Geske T, Zimmermann K: Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation. Benef Microbes 2014; 5: 367–375.
75.
Dimidi E, Christodoulides S, Scott SM, Whelan K: Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr 2017; 8: 484–494.
76.
Moayyedi P, Yuan Y, Baharith H, Ford AC: Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust 2017; 207: 166–172.
77.
Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL: Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772–1778.
78.
Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al: Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016; 315: 142–149.
79.
Daloiso V, Minacori R, Refolo P, Sacchini D, Craxi L, Gasbarrini A, et al: Ethical aspects of fecal microbiota transplantation (FMT). Eur Rev Med Pharmacol Sci 2015; 19: 3173–3180.
80.
Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al: European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569–580.
81.
Moayyedi P, Marshall JK, Yuan Y, Hunt R: Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol Hepatol 2014; 28: 66–68.
82.
Paramsothy S, Walsh AJ, Borody T, Samuel D, van den Bogaerde J, Leong RW, et al: Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol 2015; 21: 10907–10914.
83.
Pinn DM, Aroniadis OC, Brandt LJ: Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil 2015; 27: 19–29.
84.
Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, et al: Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol 2015; 21: 5359–5371.
85.
Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM: Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 2017; 46: 213–224.
86.
Shi Y, Dong Y, Huang W, Zhu D, Mao H, Su P: Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLoS One 2016; 11:e0157259.
87.
Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al: Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 2015; 30: 51–58.
88.
Colman RJ, Rubin DT: Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 1569–1581.
89.
Fang S, Kraft CS, Dhere T, Srinivasan J, Begley B, Weinstein D, et al: Successful treatment of chronic Pouchitis utilizing fecal ­microbiota transplantation (FMT): a case report. Int J Colorectal Dis 2016; 31: 1093–1094.
90.
Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M: Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol 2016; 22: 7186–7202.
91.
Fischer M, Kao D, Mehta SR, Martin T, ­Dimitry J, Keshteli AH, et al: Predictors of early failure after fecal microbiota ­transplantation for the therapy of ­Clostridium difficile infection: a multicenter study. Am J Gastroenterol 2016; 111: 1024–1031.
92.
Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, et al: The ­taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 67–77.
93.
Tariq R, Smyrk T, Pardi DS, Tremaine WJ, Khanna S: New-onset microscopic colitis in an ulcerative colitis patient after fecal microbiota transplantation. Am J Gastroenterol 2016; 111: 751–762.
94.
Mandalia A, Kraft CS, Dhere T: Diverticulitis after fecal microbiota transplant for C. difficile infection. Am J Gastroenterol 2014; 109: 1956–1967.
95.
Brechmann T, Swol J, Knop-Hammad V, Willert J, Aach M, Cruciger O, et al: Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection. World J Gastroenterol 2015; 21: 3736–3740.
96.
Alang N, Kelly CR: Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2015; 2:ofv004.
97.
Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister EB, Luna RA, et al: Transfer of viral communities between human individuals during fecal microbiota transplantation. MBio 2016; 7:e00322.
98.
Antonopoulos DA, Chang EB: Transplanting a microbial organ: the good, the bad, and the unknown. MBio 2016; 7:pii.
99.
Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al: Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 2016; 10: 387–394.
100.
Reinisch W: Fecal Microbiota Transplantation in Inflammatory Bowel Disease. Dig Dis 2017; 35: 123–126.
101.
Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al: Stool ­substitute transplant therapy for the ­eradication of Clostridium difficile infection: “RePOOPulating” the gut. Microbiome 2013; 1: 3.
102.
Shen TC, Albenberg L, Bittinger K, Chehoud C, Chen YY, Judge CA, et al: ­Engineering the gut microbiota to treat hyperammonemia. J Clin Invest 2015; 125: 2841–2850.
103.
Olesen SW, Gurry T, Alm EJ: Designing fecal microbiota transplant trials that account for differences in donor stool efficacy. Stat Methods Med Res 2017: 962280216688502.
104.
Huang Y, Wang X, Li X, Peng N: Successful fecal bacteria transplantation and nurse management for a patient with intractable functional constipation: a case study. Holist Nurs Pract 2016; 30: 116–121.
105.
Johnsen PH, Hilpusch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al: Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018; 3: 17–24.
106.
Francis CY, Morris J, Whorwell PJ: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395–402.
107.
Zaneveld JR, McMinds R, Vega Thurber R: Stress and stability: applying the Anna Karenina principle to animal microbiomes. Nat Microbiol 2017; 2: 17121.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.